WilmerHale Represents Summit Therapeutics in $25M Private Placement
WilmerHale represented Summit Therapeutics plc—a biopharmaceutical company focused on the discovery, development and commercialization of new mechanism antibiotics—in a private placement of 15,625,000 of its American Depositary Shares to the investor, Robert W. Duggan. Summit received $25 million in aggregate gross proceeds from the private placement, before expenses. The transaction
signed on December 14, 2018 and
closed on January 9, 2019, following the approval of Summit’s shareholders.
The WilmerHale team representing Summit consisted of
Brian Johnson,
Scott Lunin and
Chip McCorkle.
